請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/32878
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 陳玉怜 | |
dc.contributor.author | Chia-Chi Lin | en |
dc.contributor.author | 林家琪 | zh_TW |
dc.date.accessioned | 2021-06-13T04:17:56Z | - |
dc.date.available | 2006-08-03 | |
dc.date.copyright | 2006-08-03 | |
dc.date.issued | 2006 | |
dc.date.submitted | 2006-07-24 | |
dc.identifier.citation | Aggarwal B.B. Tumor necrosis factors receptor associated signaling molecules and their role in activation of apoptosis, JNK and NF-kappa B. Ann Rheum Dis. 2000;59:i6- i16.
Aikawa M, Rabkin E, Okada Y, Voglic SJ, et al. Lipid lowering by diet reduces matrix metalloproteinase activity and increases collagen content of rabbit atheroma. Circulation. 1998;97:2433–2444. Bacterial lipopolysaccharide and inflammatory mediators augment IL-6 secretion by human endothelial cells. J Immunol. 1989;142:144-147. Bajaj MS, Kuppuswamy MN, Manepalli AN, Bajaj SP. Transcriptional expression of tissue factor pathway inhibitor, thrombomodulin and von Willebrand factor in normal human tissues. Thromb Haemost. 1999;82:1047-1052. Baldwin AS. The NF-kappa B and I kappa B proteins: new discoveries and insights. Annu Rev Immunol. 1996;14:649-683. Bevilacqua MP, Stengelin S, Gimbrone MJ, Seed B. Endothelial leukocyte adhesion molecule 1: an inducible receptor for neutrophils related to complement regulatory proteins and lectins. Science. 1989;243:1160-1165. Boffa MC, Jackman RW, Peyri N, Boffa JF, George B. Thrombomodulin in the central nervous system. Nouv Rev Fr Hematol. 1991;33:423-429. Bustos C, Hernández-Presa MA, Ortego M, Tuñón J, Ortega L, Pérez F, et al. HMG-CoA reductase inhibition by atorvastatin reduces neointimal inflammation in a rabbit model of atherosclerosis. J Am Coll Cardiol. 1998;32:2057–2064. Carlos TM, Schwartz BR, Kovach NL, Yee E, Rosa M, Osborn L, Chi-Rosso G, Newman B, Lobb R. Vascular cell adhesion molecule-1 mediates lymphocyte adherence to cytokine-activated cultured human endothelial cells. Blood. 1990; 76:965-970. Carswell E, Old L, Kassel R, Green N, Fiore N, Williamson B. An endotoxin-induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci. 1975; 72:3666-3670. Chay CH and Pienta JK. Evidence for lectin signaling to the nuclear matrix: cellular interpretation of the glycocode. J Cell Biochem Suppl. 2000;35:123-129. Conway EM and Rosenberg RD. Tumor necrosis factor suppresses transcription of the thrombomodulin gene in endothelial cells. Mol Cell Biol. 1988;8:5588-5592. Conway EM, Nowakowski B. Biologically active thrombomodulin is synthesized by adherent synovial fluid cells and is elevated in synovial fluid of patients with rheumatoid arthritis. Blood. 1993;81:726-733. Conway EM, Van de Wouwer M, Pollefeyt S, Jurk K, Van Aken H, De Vriese A, et al. The lectin-like domain of thrombomodulin confers protection from neutrophil-mediated tissue damage by suppressing adhesion molecule expression via nuclear factor kappa B and mitogen-activated protein kinase pathways. J Exp Med. 2002;196:565-577. Esmon CT and Owen WG. The discovery of thrombomodulin. J Thromb Haemost. 2004;2:209-213. Esmon CT, Esmon NL, Harris KW. Complex formation between thrombin and thrombomodulin inhibits both thrombin-catalyzed fibrin formation and factor V activation. J Biol Chem. 1982;257:7944-7947. Essig M, Nguyen G, Prie D, Escoubet B, Sraer JD, Friedlander G. 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors increase fibrinolytic activity in rat aortic endothelial cells: role of geranylgeranylation and Rho proteins. Circ Res. 1998;83:683–690. Fukudome K, Esmon CT Identification, cloning, and regulation of a novel endothelial cell protein C/activated protein C receptor. J Biol Chem. 1994; 269:26486-26491. Gabius HJ. Concepts of tumor lectinology. J Cancer Invest. 1997;15:454-464. Goldstein JL, Brown MS. Regulation of the mevalonate pathway. Nature. 1990;343:425-430. Healy AM, Rayburn HB, Rosenberg RD, Weiler H. Absence of the blood-clotting regulator thrombomodulin causes embryonic lethality in mice before development of a functional cardiovascular system. Proc Natl Acad Sci USA. 1995;92:850-854. Hegele RA. The pathogenesis of atherosclerosis. Clin Chim Acta. 1996;246:21-38. Hernández-Perera O, Perez-Sala D, Navarro-Antolin J, Sanchez- Pascuala R, et al. Effects of the 3-hydroxy- 3-methylglutaryl-CoA reductase inhibitors, atorvastatin and simvastatin, on the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endothelial cells. J Clin Invest. 1998;101:2711–2719. Hernández-Presa MA, Martín-Ventura JL, Ortego M, Gómez-Hernández A, Tuñón J, et al. Atorvastatin reduces the expression of cyclooxygenase-2 in a rabbit model of atherosclerosis and in cultured vascular smooth muscle cells. Atherosclerosis. 2002;160:49–58. Inoue I, Goto S, Mizotani K, Awata T, Mastunaga T, Kawai S, Nakajima T, et al. Lipophilic HMG-CoA reductase inhibitor has an anti-inflammatory effect: reduction of MRNA levels for interleukin-1beta, interleukin-6, cyclooxygenase-2, and p22phox by regulation of peroxisome proliferator-activated receptor alpha (PPARalpha) in primary endothelial cells. Life Sci. 2000;67:863–876. Ireland H, Kunz G, Kyriakoulis K, Stubbs PJ, Lane DA. Thrombomodulin gene mutations associated with myocardial infarction. Circulation. 1997;96:15–18. Jirik FR, Podor TJ, Hirano T, Kishimoto T, Loskutoff DJ, Carson DA, Lotz M, Kaneta S, Satoh K, Kano S, Kanda M, Ichihara K. All hydrophobic HMG-CoA reductase inhibitors induce apoptotic death in rat pulmonary vein endothelial cells. Atherosclerosis. 2003;170:237–243. Koh KK. Effects of HMG-CoA reductase inhibitor on hemostasis. Int J Cardiol. 2000;76:23-32. Krysiak R, Okopien B, Herman Z. Effects of HMG-CoA reductase inhibitors on coagulation and fibrinolysis processes. Drugs. 2003;63:1821-1854. Kureishi Y, Luo Z, Shiojima I, Bialik A, Fulton D, Lefer DJ, Sessa WC, Walsh K The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals. Nat Med. 2000; 6:1004-1010. Laufs U, Endres M, Stagliano N, Amin-Hanjani S, Chui DS, Yang SX, et al. Neuroprotection mediated by changes in the endothelial actin cytoskeleton. J Clin Invest. 2000;106:15-24. Laufs U, Fata V L, Plutzky J, Liao JK. Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation. 1998;97:1129-1135. Laufs U, Fata VL, Liao JK. Inhibition of 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase blocks hypoxia-mediated down-regulation of endothelial nitric oxide synthase. J Biol Chem. 1997;272:31725–31729. Lentz SR, Tsiang M, and Sadler JE. Regulation of thrombomodulin by tumor necrosis factor-α: comparison of transcriptional and posttranscriptional mechanisms. Blood. 1991;77:542-550. Levine GN, Keaney JF Jr, Vita JA. Cholesterol reduction in cardiovascular disease. Clinical benefits and possible mechanisms. N Engl J Med. 1995;332:512-521. Li YH, Chen CH, Yeh PS, Lin HJ, Chang BI, Lin JC, Guo HR, Wu HL, Shi GY, et al. Functional mutation in the promoter region of thrombomodulin gene in relation to carotid atherosclerosis. Atherosclerosis. 2001;154:713–719. Li YH, Chen JH, Wu HL, Shi GY, Huang HC, Chao TH, Tsai WC, Tsai LM, Guo HR, et al. G-33A Mutation in the promoter region of thrombomodulin gene and its association with coronary artery disease and plasma soluble thrombomodulin levels. Am J Cardiol. 2000;85:8–12. Li YH, Liu SL, Shi GY, Tseng GH, Liu PY, Wu HL. Thrombomodulin plays an important role in arterial remodeling and neointima formation in mouse carotid ligation model. Thromb Haemost. 2006;95:128-133. Lin Z, Kumar A, SenBanerjee S, Staniszewski K, et al. Kruppel-like factor 2 (KLF2) regulates endothelial thrombotic function. Circ Res. 2005;96:e48-e57. Locksley, RM, Killeen, N. and Lenardo, MJ. The TNF and TNF receptor superfamilies: Integrating mammalian biology. Cell. 2001;104:487-501. Loetscher H, Pan YC, Lahm HW, Gentz R, Brockhaus M, Tabuchi H, LesslauerW. Molecular cloning and expression of the human 55 kD tumor necrosis factor receptor. Cell. 1990;61:351-359. Maesoa R, Aragoncillob P, Navarro-Cida J, Ruilopec L. M., Diazd C, et al. Effect of atorvastatin on endothelium-dependent constrictor factors in dyslipidemic rabbits. Gen Pharmacol. 2000;34:263-272. Masamura K, Oida K, Kanehara H, Suzuki J, Horie S, Ishii H, Miyamori I. Pitavastatin-induced thrombomodulin expression by endothelial cells acts via inhibition of small G proteins of the Rho family. Arterioscler Thromb Vasc Biol. 2003;23:512-517. McCachren SS, Diggs J, Weinberg JB, Dittman WA. Thrombomodulin expression by human blood monocytes and by human synovial tissue lining macrophages. Blood. 1991;78:3128-3132. Mody R, Joshi S, Chaney W. Use of lectins as diagnostic and therapeutic tools for cancer. J Pharmacol Toxicol Methods. 1995;33:1-10. Mundy G, Garrett R, Harris S, Chan J, Chen D, Rossini G, Boyce B, et al. Stimulation of bone formation in vitro and in rodents by statins. Science. 1999;286:1946-1949. Nawroth PP, Bank I, Handley D, Cassimeris J, Chess L, Stern D. Tumor necrosis factor/cachectin interacts with endothelial cell receptors to induce release of interleukin 1. J Exp Med. 1986;163:1363-1375. Ohlin AK, Holm J, Hillarp A. Genetic variation in the human thrombomodulin promoter locus and prognosis after acute coronary syndrome. Thromb Res. 2004;113:319-326. Old LJ. Tumor necrosis factor (TNF). Science. 1985;230:630-632. Ortego M, Bustos C, Hernández-Presa MA, Tuñón J, Díaz C, Hernández G, et al. Atorvastatin reduces NF-κB activation and chemokine expression in vascular smooth muscle cells and mononuclear cells. Atherosclerosis. 1999;147:253–61. Osborn L, Hession C, Tizard R, Vassallo C, Luhowskyj S, Chi-Rosso. Direct expression cloning of vascular cell adhesion molecule 1, a cytokine-induced endothelial protein that binds to lymphocytes. Cell. 1989;59:1203-1211. Owen WG and Esmon CT. Functional properties of an endothelial cell cofactor for thrombin-catalyzed activation of protein C. J Biol Chem.1981;256:5532-5535. Pedersen TR, Kjekshus J, Berg K, Haghfelt T, Faergeman O, Faergeman G, et al. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Atheroscler Suppl. 2004;5:81-87. Pober JS, Lapierre LA, Stolpen AH, Brock TA, Springer TA, Fiers W, et al. Activation of cultured human endothelial cells by recombinant lymphotoxin: comparison with tumor necrosis factor and interleukin 1 species. J Immunol. 1987;138:3319-3324. Rabausch K, Bretschneider E, Sarbia M, Meyer-Kirchrath J, Censarek P, et al. Regulation of thrombomodulin expression in human vascular smooth muscle cells by COX-2–derived prostaglandins. Circ Res. 2005;96:e1-e6. Raife TJ, Lager DJ, Madison KC, Piette WW, Howard EJ, Sturm MT, et al. Thrombomodulin expression by human keratinocytes. Induction of cofactor activity during epidermal differentiation. J Clin Invest. 1994;93:1846-1851. Rice GE, Bevilacqua MP. An inducible endothelial cell surface glycoprotein mediates melanoma adhesion. Science. 1989;246:1303-1306. Rikitake Y, Kawashima S, Takeshita S, Yamashita T, Azumi H, et al. Anti-oxidative properties of fluvastatin, an HMG-CoA reductase inhibitor, contribute to prevention of atherosclerosis in cholesterol-fed rabbits. Atherosclerosis. 2001;154:87–96. Rosenson RS, Tangney CC. Antiatherothrombotic properties of statins: implications for cardiovascular event reduction. JAMA. 1998;279:1643-1650. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med. 1999;340:115-126. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature. 1993;362:801-809. Schall TJ, Lewis M, Koller KJ, Lee A, Rice GC, Wong GH, Gatanaga T, et al. Molecular cloning and expression of a receptor for human tumor necrosis factor. Cell. 1990;61:361-370. Sheehan M, Wong HR, Hake PW, Malhotra V, O'Connor M, Zingarelli B. Parthenolide, an inhibitor of the nuclear factor-kappaB pathway, ameliorates cardiovascular derangement and outcome in endotoxic shock in rodents. Mol Pharmacol. 2002;61:963-963. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med. 1995;333:1301-1307. Shi CS, Shi GY, Chang YS, Han HS, Kuo CH, Liu C, Huang HC, et al. Evidence of human thrombomodulin domain as a novel angiogenic factor. Circulation. 2005;111:1627-1636. Shi J, Wang J, Zheng H, Ling W, Joseph J, Li D, Mehta JL, et al. Hauer-Jensen M. Statins increase thrombomodulin expression and function in human endothelial cells by a nitric oxide-dependent mechanism and counteract tumor necrosis factor alpha-induced thrombomodulin downregulation. Blood Coagul Fibrinolysis. 2003;14:575-585. Singh R, Wang B, Shirvaikar A, Khan S, Kamat S, Schelling JR, et al. The IL-1 receptor and Rho directly associate to drive cell activation in inflammation. J Clin Invest. 1999;103:1561-1570. Smith CA, Davis T, Anderson D, Solam L, Beckmann MP, Jerzy R, et al. A receptor for tumor necrosis factor defines an unusual family of cellular and viral proteins. Science. 1990;248:1019-1023. Sohn RH, Deming CB, Johns DC, Champion HC, Bian C, et al. Regulation of endothelial thrombomodulin expression by inflammatory cytokines is mediated by activation of nuclear factor-kappa B. Blood. 2005;105:3910-3917. Speiser W, Kapiotis S, Kopp CW, Simonitsch I, Jilma B, et al. Effect of intradermal tumor necrosis factor-alpha-induced inflammation on coagulation factors in dermal vessel endothelium. An in vivo study of human skin biopsies. Thromb Haemost. 2001;85:362-367. Steinberg D, Parthasarathy S, Carew TE, Khoo JC, Witztum JL. Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity. N Engl J Med. 1989;320:915-924. Suzuki K, Kusumoto S, Deyashiki Y, Nishioka J, Maruyama I, Zushi M, et al. Structure and expression of human thrombomodulin, a thrombin receptor on endothelium acting as a cofactor for protein C activation. EMBO J. 1987;6:1891-1897. Suzuki K, Nishioka J, Hayashi T, Kosaka Y. Functionally active thrombomodulin is present in human platelets. J Biochem (Tokyo). 1988;104:628-632. Takemoto M, Liao JK. Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors. Arterioscler Thromb Vasc Biol. 2001;21:1712-1719. Tandon V, Bano G, Khajuria V, Parihar A, Gupta S. Pleiotropic effects of statins. Indian J Pharmacol. 2005;37:77-85. Undas A, Brummel-Ziedins KE, Mann KG. Statins and blood coagulation. Arterioscler Thromb Vasc Biol. 2005;25:287-294. Van AL, D’Souza-Schorey C. Rho GTPases and signaling networks. Genes Dev. 1997;11:2295-2322. Wang HR, Li JJ, Huang CX, Jiang H. Fluvastatin inhibits the expression of tumor necrosis factor-alpha and activation of nuclear factor-kappaB in human endothelial cells stimulated by C-reactive protein. Clin Chirn Acta. 2006;353:53-60. Waugh JM, Li-Hawkins J, Yuksel E, Kuo MD, Cifra PN, Hilfiker PR, Geske R, Chawla M, Thomas J, Shenaq SM, Dake MD, Woo SL. Thrombomodulin overexpression to limit neointima formation. Circulation. 2000;102:332-337. Weiler H. Mouse models of thrombosis: thrombomodulin. Thromb Haemost. 2004;92:467-477. Weitz-Schmidt G, Welzenbach K, Brinkmann V, Kamata T, et al. Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site. Nat Med. 2001;7:687-692. Wojciak-Stothard B, Ridley AJ. Rho GTPases and the regulation of endothelial permeability. Vascul Pharmacol. 2003;39:187-199. Wong VL, Hofman FM, Ishii H, Fisher M. Regional distribution of thrombomodulin in human brain. Brain Res. 1991;556:1-5. Wu CC, Su MJ, Chi JF, et al. The effect of hypercholesterolemia on the sodium inward currents in cardiac myocyte. J Mol Cell Cardiol. 1995;27:1263-1269. Zhang F, Yu W, Hargrove JL, Greenspan P, Dean RG, Taylor EW, Hartle DK Inhibition of TNF-alpha induced ICAM-1, VCAM-1 and E-selectin expression by selenium. Atherosclerosis. 2002;161:381-386. Zhang FL, Casey PJ. Protein prenylation: molecular mechanisms and functional consequences. Annu Rev Biochem. 1996;65:241-269. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/32878 | - |
dc.description.abstract | 血栓調節蛋白 (thrombomodulin, TM) 為血管內皮細胞膜上的一種醣蛋白,可與血液中的血栓蛋白結合,使血栓蛋白無法開啟下游的凝血機轉。Atorvastatin (Lipitor®) 是一種三氫氧基三甲基穀胱胺基輔酶還原酶的抑制劑 (HMG-CoA reductase inhibitor),在臨床上常被用來治療心血管疾病,這種藥物可顯著降低病患的罹患率及死亡率,過去報告指出statins藥物能夠拮抗由腫瘤壞死因子(tumor necrosis factor-alpha, TNF-α) 所抑制的TM表現,因此我們想要探討atorvastatin對於餵食膽固醇兔子或對於正常及TNF-α處理人類主動脈內皮細胞所誘發TM的表現及其影響的相關機制。
在動物實驗中,我們取正常、餵食三週及九週膽固醇飼料以及同時餵食atorvastatin及膽固醇飼料三週、九週的紐西蘭白兔的主動脈,可發現在正常或無動脈硬化斑塊病灶處的血管中,TM會表現在內皮細胞上。而在病灶區的TM除了表現在內皮細胞,也會在斑塊中的平滑肌細胞表現。另外我們將主動脈的蛋白質萃取出來進行西方轉漬法,發現除了餵食三週膽固醇的TM表現下降之外,餵食九週膽固醇、同時餵食atorvastatin及膽固醇飼料三週、九週的TM表現與控制組相比皆有上升的趨勢,且有餵食atorvastatin的組別的TM表現比單以餵食膽固醇兔子來的高。在細胞實驗我們發現以TNF-α處理人類主動脈內皮細胞,內皮細胞TM的表現會隨著TNF-α濃度及處理時間的增加,而有顯著減少的趨勢;以atorvastatin藥物處理人類主動脈內皮細胞,其TM的表現隨著藥物濃度及時間的增加而有增加的趨勢;若先以atorvastatin處理,再以TNF-α刺激,可發現atorvastatin能夠拮抗因TNF-α所造成TM表現降低的情形。進一步,我們發現以TNF-α處理人類主動脈內皮細胞,nuclear factor-kappa B (NF-κB)會被活化,而以atorvastatin前處理,再以TNF-α處理人類主動脈內皮細胞,NF-κB活化的情形顯著減少。若以NF-κB抑制劑 (parthenolide) 處理細胞時,可發現parthenolide也可拮抗因TNF-α所導致的TM表現下降情形,因此atorvastatin拮抗因TNF-α所導致的TM表現下降,是因為抑制NF-κB的活化。由動物實驗及細胞實驗結果可發現atorvastatin增加TM的表現,而這也許是atorvastatin保護血管內皮細胞的一種方法。 | zh_TW |
dc.description.abstract | TM is an integral membrane glycoprotein, which functions in anticoagulation by virtue of eliminating thrombin from the blood. Formation of the thrombin-TM complex can effectively activate protein C, which in turn catalyzes the proteolytic inactivation of blood coagulation factor Va and VIIIa, leading to downregulation of blood coagulation cascade. The main feature of the antithrombotic properties of endothelial cells is an increase in the expression of thrombomodulin (TM). The 3-hydroxyl-3-methyl-glutaryl coenzyme A reductase inhibitor, atorvastatin, can protect the vasculature independent of their lipid-lowering activity. We investigated the effect of atorvastatin on the expression of TM and their underlying mechanisms in cholesterol-fed rabbits and in human aortic endothelial cells (HAECs) with or without tumor necrosis-alpha (TNF-α) treatment. In vivo experiments, we found that the expression of TM appeared not only in endothelial cells but also in smooth muscle cells at atherosclerotic lesions.
In vitro experiments, TNF-α treatment decreased the expression of TM in a time- and dose-dependent manner in HAECs. Atorvastatin pretreatment upregulated the expression of TM in a time- and dose-dependent manner in HAECs with or without TNF-α treatment. TNF-α treatment increased the activation of nuclear factor-kappa B (NF-κB), and atorvastatin pretreatment could inverse the effect. In addition, blocking the activation of NF-TM is an integral membrane glycoprotein, which functions in anticoagulation by virtue of eliminating thrombin from the blood. Formation of the thrombin-TM complex can effectively activate protein C, which in turn catalyzes the proteolytic inactivation of blood coagulation factor Va and VIIIa, leading to downregulation of blood coagulation cascade. The main feature of the antithrombotic properties of endothelial cells is an increase in the expression of thrombomodulin (TM). The 3-hydroxyl-3-methyl-glutaryl coenzyme A reductase inhibitor, atorvastatin, can protect the vasculature independent of their lipid-lowering activity. We investigated the effect of atorvastatin on the expression of TM and their underlying mechanisms in cholesterol-fed rabbits and in human aortic endothelial cells (HAECs) with or without tumor necrosis-alpha (TNF-α) treatment. In vivo experiments, we found that the expression of TM appeared not only in endothelial cells but also in smooth muscle cells at atherosclerotic lesions. In vitro experiments, TNF-α treatment decreased the expression of TM in a time- and dose-dependent manner in HAECs. Atorvastatin pretreatment upregulated the expression of TM in a time- and dose-dependent manner in HAECs with or without TNF-α treatment. TNF-α treatment increased the activation of nuclear factor-kappa B (NF-κB), and atorvastatin pretreatment could inverse the effect. In addition, blocking the activation of NF-κB could reverse the downregulation of TM by TNF-α treatment in HAECs. Atorvastatin-mediated increase in TM expression by endothelial cells may contribute to the beneficial effects on endothelial function. | en |
dc.description.provenance | Made available in DSpace on 2021-06-13T04:17:56Z (GMT). No. of bitstreams: 1 ntu-95-R93446010-1.pdf: 1117529 bytes, checksum: ccbdc3126cc48508f5265df50d34f5a3 (MD5) Previous issue date: 2006 | en |
dc.description.tableofcontents | 縮寫表(2)
中文摘要(4) 英文摘要(6) 壹、緒論(8) 一、動脈硬化 (atherosclerosis) 與內皮細胞 (endothelial cells) 的關係(9) 二、動脈硬化 (atherosclerosis) 與腫瘤壞死因子 (TNF-α) 的關係(11) 三、血栓調節蛋白 (Thrombomodulin, TM)(12) 四、三氫氧基三甲基穀胱胺基輔酶A還原酶抑制劑 (Statins)(14) 五、研究目的(17) 貳、材料與方法(18) 一、儀器設備(19) 二、實驗材料與試劑(20) 三、實驗用溶液配方(24) 四、實驗方法(27) 參、實驗結果(37) 肆、討論與結論(46) 伍、附圖(53) 陸、參考文獻(66) 柒、附錄(81) | |
dc.language.iso | zh-TW | |
dc.title | 探討atorvastatin在人類主動脈內皮細胞及餵食膽固醇
飼料兔子中血栓調節蛋白的表現及其相關機轉 | zh_TW |
dc.title | The effects of atorvastatin on thrombomodulin expression in
human aortic endothelial cells and cholesterol-fed rabbits. | en |
dc.type | Thesis | |
dc.date.schoolyear | 94-2 | |
dc.description.degree | 碩士 | |
dc.contributor.oralexamcommittee | 王淑美,王寧,吳華林,林淑華 | |
dc.subject.keyword | 膽固醇飼料兔子,人類主動脈內皮細胞,血栓調節蛋白, | zh_TW |
dc.subject.keyword | atrovastatin,human aortic endothelial cells,choleseterol-fed rabbits, | en |
dc.relation.page | 83 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2006-07-25 | |
dc.contributor.author-college | 醫學院 | zh_TW |
dc.contributor.author-dept | 解剖學研究所 | zh_TW |
顯示於系所單位: | 解剖學暨細胞生物學科所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-95-1.pdf 目前未授權公開取用 | 1.09 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。